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Aim: Research shows that subclinical hypothyroidism (SCH) is related to an increased carotid
intima – media thickness (CIMT), a surrogate marker of subclinical cardiovascular disease (CVD). It
is controversial whether or not SCH should be treated to reduce CVD morbidity and mortality. This
meta-analysis aimed to determine whether SCH is associated with an increase in CIMT as compared
to Euthyroidism (EU) and whether thyroxin (T4) treatment in SCH can reverse the change in CIMT.
Methods: Two independent reviewers conducted an extensive database research up to December
2016. A total of 12 clinical trials discussed the effect of Thyroxin on CIMT values at pre- and posttreatment in subjects with SCH.
Results: CIMT was significantly higher among SCH (n = 280) as compared to EU controls (n = 263)
at baseline; the pooled weighted mean difference (WMD) of CIMT was 0.44 mm [95% confidence
interval (CI) 0.14, 0.74], p = 0.004; I2 = 65%. After treatment with thyroxin in subjects with SCH
(n = 314), there was a statistically significant decrease in CIMT from pre- to post-treatment; the
pooled WMD of CIMT decrease was [WMD −0.32; 95% CI (−0.47, −0.16), p =＜ 0.0001; I2 = 2%],
and it was no longer different from EU controls [WMD 0.13 mm; 95% CI (−0.04, 0.30); p = 0.14;
I2 = 27%]. The total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL) were
higher in SCH as compared to EU controls and decreased significantly after treatment with thyroxin.
Conclusion: This meta-analysis shows that thyroxin therapy in subjects with SCH significantly
decreases CIMT and improves lipid profile, modifiable CVD risk factors. Thyroid hormone replacement in subjects with SCH may play a role in slowing down or preventing the progression of atherosclerosis.
Key words: Subclinical hypothyroidism, Euthyroid/Euthyroidism, Carotid intima – media thickness,
Thyroxin treatment, Dyslipidemia, Clinical trials, Meta-analysis
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Introduction
How important is it to treat subclinical hypothyroidism (SCH) ? This question leads to a chain of controversial discussions. SCH is a condition with an elevated thyroid-stimulating hormone (TSH) in the set1
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ting of normal free thyroid hormone levels, both FT3
and FT4 1). In the recent past, the detection of SCH
has been increasing with evolving diagnostic tests. The
prevalence of SCH is greater than that of type 2 diabetes mellitus (estimated to be 5 – 10%) and with an
increased occurrence among females and the elderly 2-4).
The prevalence of SCH is almost up to 20% in
females older than 60 years 2).
SCH has also been considered to increase the risk
of atherosclerosis alongside overt hypothyroidism 5, 6).
The association of overt hypothyroidism with atherosclerotic disease has been well established, and treating
those patients with levothyroxine has shown proven
benefits in reducing cardiovascular risk 7). There is evidence that SCH had effects on some important cardiovascular risk factors, such as high blood pressure,
dyslipidemia, and altered coagulability 8, 9). However,
how significant a role does SCH play as an independent risk factor for atherosclerosis was debatable, until
a recent population-based study proved otherwise 10, 11).
Carotid Intima – media thickness (CIMT), measured using carotid ultrasonography, is trusted to be a
good marker of atherosclerotic changes in early stages
apart from being accepted as a surrogate endpoint for
cardiovascular events 12, 13). Many studies have shown
that SCH is independently related to a significant increase in CIMT in relatively healthy subjects when compared with euthyroid (EU) healthy matched groups 14-19).
Several studies, including some randomized controlled
trials, have shown reduced cardiovascular risk, including a significant reduction in CIMT in subjects with
SCH treated with levothyroxin 15, 17, 18, 20-28).
The primary focus of this review and meta-analysis is to determine the differences of CIMT between
subjects with SCH and EU controls at baseline as well
as to demonstrate the effects of thyroxine treatment
on CIMT reduction from pre-to-post treatment after
a follow-up period. We hypothesized that “thyroxin
treatment in subjects with SCH causes a decrease in
CIMT values from pre-to-post treatment.”
Methods
We conducted this systematic review and metaanalysis using the PRISMA statement as guideline 29).
Eligibility Criteria
In this systematic review and meta-analysis, we
included the clinical trials that reported the treatment
of subjects with SCH and discussed the effects of thyroxin treatment on CIMT reduction in subjects with
SCH from pre- to post-treatment during a follow-up
period. Our hypothesis was to analyze “the effects of
thyroxin treatment on CIMT reduction in patients
2

with SCH during a follow-up period.” We selected
original published clinical trials with no language and
regional limitations. According to the hypothesis, we
defined a strict inclusion and exclusion criteria as
described below.
Inclusion Criteria were as Follows
(1) Studies investigating subjects with SCH (the
mean pretreatment basal serum TSH concentration
must have been above the upper limit of normal for
the assay used in the study, but less than 20 mU/L
along with a normal T4 level) and comparing them
with subjects with EU; (2) Use of the ultrasound
method to measure CIMT both in subjects with SCH
and EU at baseline; and (3) Use of the ultrasound
method to measure CIMT in subjects with SCH at
pre- and post-treatment with thyroxin along a followup period. We included studies that discussed demographically, anthropometrically, and metabolically
matched SCH and EU control groups to discuss the
effect of SCH on CIMT and the role of thyroxin
treatment on CIMT reduction in subjects with SCH.
We excluded all studies that discussed subjects
with chronic diseases/risk factors that can potentially
affect CIMT and thyroid function tests. Exclusion criteria were as follows: (1) Use of overt clinical hypothyroidism/hyperthyroidism subjects; (2) Use of subjects
on any medications to treat hypo and hyper functions
of thyroid, including thyroid cancer; (3) Use of any
subjects with average TSH ＞ 20 (mIU/l); (4) Use of
any subjects with established coronary artery disease
(CAD), congestive heart failure (CHF), obesity (BMI
≥ 30 kg/m2), chronic liver disease, chronic kidney failure, chronic inflammatory diseases, hypophyseal
insufficiency, or any type of cancer; (5) Use of any
pregnant, lactating, or menopausal women; (6) Use of
any subject using medications that can potentially
alter thyroid function tests (e.g., amiodarone, carbamazepine, carbidopa, phenytoin, furosemide, haloperidol, heparin, interferon, levodopa, Lithium, metoclopramide, propranolol, primidone, rifampicin, and valproic acid.) (7) Use of any subject using medications
that can potentially affect hormonal changes in the
body (e.g., antidiabetics, glucocorticoid therapy, OCP,
steroids, GnRH agonists and antagonists, insulin-sensitizing drugs, antiandrogens, and aspirin), as well as
affect blood pressure (anti-hypertensives) or lipid levels (anti-hyperlipidemics); and (8) Use of different
therapeutic approaches apart from thyroxin/T4 treatment of subjects with SCH.
Information Sources and Search Strategy
An extensive literature search, not limited by language and regions, was performed, which was directed
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Fig. 1. PRISMA search Flow Diagram for CIMT values at baseline in SCH and EU subjects as well as CIMT
values at pre-to-post Thyroxin treatment in SCH subjects.

to our hypothesis by two independent reviewers
(M.A., Y.K.) via Medline using PubMed and Ovid SP,
Web of Science, Cochrane Central Register of Controlled Trials, and EMBASE, up to December 2016.
The following medical subject headings [Mesh] were
used to select the relevant studies for a final review
and meta-analysis: SCH [Mesh] OR SCH [Mesh]
AND thyroxin [Mesh] OR 3, 5, 3’, 5’-tetraiodothyronine [Mesh] OR T4 [Mesh] AND CIMT [Mesh] OR
CIMT [Mesh] OR carotid atherosclerosis [Mesh] AND
(random [Free Item] OR randomized controlled trials
[Free Item] OR RCTs [Free Item]). Furthermore, the

reference sections of the finally selected studies were
screened for additional eligible studies. In rare cases,
authors of the relevant studies were contacted when
more information or clarification was needed. Fig. 1
shows the PRISMA flow diagram of the effect of thyroxin treatment on the reduction of CIMT values in
subjects with SCH at pre- to post-treatment.
Study Selection
A total of 12 original studies included in the
final review had a sample size ranging from 20 to
56 15, 17, 18, 20, 21, 23-28, 30). The total sample of subjects
3
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Fig. 2. Risk of bias graph for randomized controlled trials using the Cochrane risk of bias tool.
Review authors’ judgments about each risk of bias item presented as percentages across all
included studies.

with SCH was (n = 380) and that with EU controls
was (n = 367). First, we screened 38 studies that discussed CIMT values in subjects with SCH and EU at
baseline. Of these 38 studies, only 12 studies were
clinical trials that discussed the treatment of SCH
with thyroxin and measured CIMT values at pre- and
post-treatment with a follow-up period. We excluded
all other studies (n = 26) as these were case control,
and/or cross-sectional, case reports/editorials, and
none of these studies discussed the treatment of subjects with SCH. Among these finally selected 12 studies for review, 11 studies were included in the metaanalysis as the study by Köroglu et al. 2012 24) did not
report any mean CIMT values at pre- and post-treatment with thyroxin.

tia interface. Any type of disagreement in data collection was resolved by discussion with a fourth reviewer
(Kandimalla, Y). In all clinical trials included in this
meta-analysis, the confounding factors that may affect
CIMT, for example, use of recent previous/present thyroid medications or other medications that affect thyroid hormones, any thyroid disease other than SCH,
smoking, HTN, DM, CVD, stroke, chronic liver disease, and chronic kidney disease were balanced between
subjects with SCH and EU controls by the respective
authors of each included study. All studies in this
review have clearly mentioned about the research
approval of the institutional ethical committee and
participants in the studies completed and signed the
informed consent form.

Data Extraction and Quality Assessment
Three authors (Machavarapu, A; Saxena, A;
Nguyen, M) extracted the data on an excel sheet independently from eligible studies related to subjects with
SCH, EU controls, as well as the treatment of subjects
with SCH. The data extracted included first author
last name, publication year, study design, country of
origin, study subjects’ age, sample size, gender, cut-off
TSH value to diagnose SCH, systolic blood pressure
(SBP), diastolic blood pressure (DBP), lipid levels [total
cholesterol (TC), triglycerides (TG) high-density lipoprotein (HDL), low-density lipoprotein (LDL), TSH],
and CIMT in subjects with EU and SCH at baseline
as well as at pre- and post-treatment with thyroxin. In
different studies selected for a review, different biochemical and hormones assays were used to measure
all classes of lipids and TSH levels. All studies used
Doppler ultrasound of carotid arteries to measure
CIMT. CIMT was assessed as the distance between
the lumen – intima interface and the media – adventi-

Data Synthesis and Analysis
The baseline mean CIMT as well as the standard
deviations of CIMT were extracted in subjects with
SCH and EU controls. The mean CIMT values and
standard deviations were also extracted in subjects
with SCH at pre- and post-treatment with thyroxin.
We used RevMan 5 free version to conduct the data
analysis 31). The overall variation among studies termed
as heterogeneity was calculated by I2 (Tau2) statistics.
The square root of this number is the estimated standard deviation of the underlying effects across studies.
The estimate of the between-study variance can be
measured via a fixed- or random-effect model. We calculated the weighted mean difference (WMD) or the
standardized mean difference (SMD) with a 95% confidence interval (CI) to calculate the pooled effect size
using a fixed- or random-effect model as appropriate.
Under a fixed-effect model, we assume that there is
one true effect size that is shared by all the included
studies. It follows that the combined effect is our esti-

4
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mate of this common effect size. In contrast, under a
random-effect model, we allow that the true effect
could vary from study to study and we try to estimate
the mean of a distribution of true effects. Large studies may produce more precise estimates of a true effect
than small studies, but each study estimates a different
effect size. Therefore, the weights assigned under a
random-effect model are more balanced as compared
with that in a fixed-effect model. WMD with a 95%
CI of CIMT values was measured for subjects with
SCH and EU at baseline. WMD with a 95% CI of
CIMT was also measured for subjects with SCH at
pre- and post-treatment periods with thyroxin. Statistical heterogeneity was tested using Tau2 with p ＜ 0.05
considered as significant.
Two authors (Khan, IM; Aziz, M) used the
Cochrane risk of bias tool to determine the risk of a
bias graph (Fig. 2) and that of a bias summary (Fig. 3)
in individual studies per methodological quality of
included clinical trials. The Cochrane risk of bias tool
is based on the following items: Random sequence
generation, allocation concealment, blinding of participant and personnel, outcome data blinding, incomplete outcome data, selective reporting, and other bias.
A subgroup/sensitivity analysis was used to explore the
potential sources of between-studies heterogeneity
according to the type of studies, study quality by the
JADAD score as a low ( ≤ 2 score) or high ( ≥ 3 score)
range of quality score, BMI ＜ 25 kg/m2, TSH values
as ≤ 10 mIU/l and ＞ 10 mIU/l, and duration of treatment as less than 6 months and more than 6 months.
Potential publication bias was assessed and represented
graphically with funnel plots of WMD or SMD versus
standard error 32, 33). The decision to use the results of
the Cochrane risk of bias assessment tool and publication bias among studies was taken by discussing with
senior authors (Nasir, K; Kandimalla, Y; Veledar, E)

Fig. 3. Risk of bias summary: Review authors’ judgments
about each risk of bias item for each included study.

Results
Study Characteristics
Table 1 shows the characteristics of subjects with
SCH and EU controls. All 12 studies discussed the
comparison of CIMT values in subjects with SCH
and EU at baseline as well as the effect of thyroxin
treatment on CIMT reduction in subjects with SCH.
However, only 9 out of 12 studies reported the mean
CIMT values of subjects with SCH and EU controls
at baseline and 11 out of 12 studies reported the effect
of thyroxin treatment on CIMT reduction from preto post-treatment. Table 2 shows the JADAD score
for the quality of each study, duration of follow-up,
TSH and CIMT values at pre- and post-treatment,
and change and percentage change in TSH and CIMT

values from pre- to post-treatment.
CIMT Values Among Subjects with SCH and EU at
Baseline
The 9 clinical trials reported differences of CIMT
values among subjects with SCH and EU controls at
baseline (SCH, n = 280; EU, n = 263). There was a statistically significant heterogeneity among studies
(I2 = 65%; p = 0.004). A random-effect model was used
to calculate the pooled WMD and the overall WMD
showed significantly higher CIMT values among subjects with SCH as compared to those with EU [WMD
0.44 mm; 95% CI (0.14, 0.74); p = 0.004] (Fig. 4a).
5
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Table 1. Characteristics of study population
Author(s),
Year Published
& Study Type

Country

Sample
(SCH/EU)

Age (yr)
(SCH/EU);
Female %

Monzani et al.
2004 18);
Clinical trial

Italy

45/32

37±11/
35±10

＞ 3.6

Duman et al.
2007 23);
Clinical trial

Turkey

20/20

37.0±12.6/
37.0±12.6

Adrees et al.
2009 20);
Clinical trial

Ireland

56/56

Kim et al.
2009 17);
Clinical trial

Korea

36/32

Kebapcilar et al.
2010 15);
Clinical trial

Turkey

CIMT (mm)
at baseline:
SCH/EU

Exclusion criteria used

SCH and EU
Groups matched
for

6.03±8.4/
1.19±1.6

0.76±0.14/
0.63±0.07

Thyroid Rx., subjects ＞ 55 yr, obese (BMI ＞ 30 kg/
m2), smoking, HTN, DM, CVD, CRF, CLD.

sex, age, BMI

＞ 4.2

10.9±5.8/
2.3±0.8

0.65±0.99/
0.54±0.10

Taking any medication, Obesity (BMI＞ 30 kg/m2),
DM, HTN, CHD, CLD, CRF, FH, PVD, age ＜ 18
years or ＞ 60 years, smoking, menopause, pregnancy.

sex, age.

50±9/
NR

NR

13.2±4.5/
1.9±1.0

0.82±0.2/
NR

Hx. of IHD, TIA, HTN, DM, or impaired fasting
glycaemia, smoking, coeliac disease, pernicious anemia.

age, BMI.

36.0±6.2/
36.1±5.4

＞ 5.5

11.48±4.70/
1.60±0.60

0.67±0.11/
0.57±0.08

Hx. of thyroid disease or Rx., thyroidectomy, or
radioiodine therapy, DM, HTN, serum Creatinine
＞ 1.3 mg/dL, smoking, statin use, previous pregnancy in the last 1 year, postmenopausal state.

gender, age,
BMI

age, smoking
habit, waist
circumference,
BMI.

38/19

49.47±10.04/
49.95±8.12

47.59±8.4/
43.36±9.8

TSH cutoff TSH (mIU/l)
value
at baseline
(mIU/l)
(SCH/EU)

＞ 5.0

11.26±7.54/
1.48±1.12

0.64±0.13/
0.57±0.08

DM, CHD, CLD, CRF, other systemic diseases,
morbid obesity, FH, cancer. MEDS: anti-hyperlipidemics, antihypertensives, acetylsalicylic acid, antihistamines, corticosteroids, HRT, multivitamins, or
excessive alcohol.

＞ 4.0

6.79±2.0/
6.77±1.9

0.66±0.11/
NR

Hx. of previous thyroid disease, THS ＞ 12 mIU/ml,
obesity, HTN, DM, CAD, CLD, CRF, alcohol use.
＊
MEDS : amiodarone, corticosteroids, estrogens, lithium, anti-lipids, diuretics, anti-diabetics, antihypertensive, and drugs to treat obesity.

NR

Cabral et al.
2011 30);
Clinical trial

Brazil

32/NR

Koroglu et al.
2012 24);
Clinical trial

Turkey

30/NR

44.0±11.6/
47.9±14.6

NR

7.5±1.5/
6.8±1.4

NR/NR

CAD, CLD, CRF, chronic inflammatory disease,
hypophyseal insufficiency, Thyroid Rx. in recent 3
months, use of statins, use of HRT.

NR

Akkoca et al.
2014 21);
Clinical trial

Turkey

20/20

34.47±1.43/
35.25±2.21

NR

8.97±1.1/
3.50±0.43

0.74±0.63/
0.39±0.72

Hx. of thyroid Rx. , HTN, DM, CAD, CLD, CRF,
cancer, FH, use of lipid lowering drugs, BMI ＜ 20
kg/m2 or＞ 30 kg/m2, smoking.

Age, height,
weight, BMI

Unsal et al.
2014 25);
Clinical trial

Turkey

56/46

41.32±14.48/
36.07±10.58

＞ 4.2

Yazici et al.
2014 28);
Clinical trial

Turkey

43/30

35.2±10.7/
34.5±8.2

＞4

Cerbone et al.
2016 26);
Clinical trial

Italy

39/39

9.18±3.56/
9.45±3.62;

Niknam et al.
2015 27);
Clinical trial

Iran

25/25

35.9±7.6/
37.5±7.3

＞ 4.5

Hx. of thyroid disease or Rx, thyroidectomy, obesity,
6.77±2.902/ 0.533±0.112/
DM, HTN, CVD, CLD, CRF, radioiodine therapy,
1.65±0.913
0.5±0.086
statin use, alcohol use.

NR

0.51±0.09/
0.48±0.04

DM, HTN, heart failure, IHD, valvular disease,
CLD, CRF, rheumatological disease, malignancy.
MEDS: antihypertensives, antihyperlipidemics, acetylsalicylic acid, HRT.

Sex, age, SBP,
DBP, BMI

6.30±1.01/
2.92±0.68

0.44±0.08/
0.44±0.06

Chronic diseases, chromosomal and genetic syndromes, previous or current thyroid diseases, use of
drugs that may interfere with thyroid function, previous irradiation in the neck region, detection of
SCH at neonatal screening, familial history of genetic
lipid disorders or early CVD

age, height,
BMI, SBP,
DBP,

7.19±1.29/
2.4±0.55

0.56±0.09/
0.58±0.08

Rx. of hypothyroidism, CVD, CRF, CLD, malignancies, or CVA, HTN, DM, obesity (BMI＞ 30 kg/
m2), smoking, pregnancy, lactating women.

sex, age.

6.0±1.4/
2.0±0.3

SCH = Subclinical Hypothyroidism, NR = Not reported, Hx = History of, Rx = Treatment of, HTN = Hypertension, DM = Diabetes Mellitus, ATH
Disease = atherosclerotic disease (e.g. CAD, PAD etc. ), CAD = Coronary Artery Disease, IHD = Ischemic Heart Disease, CHD = Coronary Heart Disease, CHF = Congestive Heart Failure, CLD = Chronic Liver Disease, CRF = Chronic Renal Failure, CARS = Coronary Artery Revascularization Surgery,
TC = Total cholesterol, HCL = Hypercholesterolemia, CAH = congenital adrenal hyperplasia, HPRL = hyperprolactinemia, WC = Waist Circumference,
FH = Familial Hypercholesterolemia, CD = Cushing’s disease, TIA = Transient Ischemic Attacks, HRT = Hormone Replacement Therapy,
MNG = Multinodular Goiter, DBP = Diastolic Blood Pressure, SBP = Systolic Blood pressure. MEDS＊ use of any drugs that alter Thyroid function test.
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Table 2. Characteristics of SCH subjects: Pre-to-Post Treatment (INCLUDED ONLY STUDIES THAT DISCUSSED TREATMNET OF SCH)
Authors

N (SCH):
Dose of Duration TSH (mIU/ TSH (mIU/
Pre-Rx/ JADAD Primary Rx.
%
Thyroxin of Rx.
L) in SCH L) in SCH Change
Post-Rx; % Score
disease given
change
(µg/day)
(Mo)
(pre-Rx)
(Post-Rx)
Females

CIMT
(mm) in
SCH
(Pre-Rx)

CIMT
(mm) in
SCH
(Post-Rx)

Change

%
change

Monzani et al.
2004 18)

23/23;
82%

4

SCH

T4

25

6

6.03±8.4

1.32±1.7

−4.71 −78% 0.76±0.14 0.67±0.13

−0.09

−12%

Duman et al.
2007 23)

20/20;
100%

4

SCH

T4

25

8

10.9±5.8

2.0±1.1

−8.9 −82% 0.65±0.99 0.55±0.08

−0.1

−15%

Adrees et al.
2009 20)

56/52;
100%

1

SCH

T4

50

18

13.2±4.5

1.6±1.8

−0.11

−13.4%

Kim et al.
2009 17)

36/28;
86.1%

3

SCH

T4

67

18

11.48±4.70

1.26±3.30 −10.22 −89% 0.67±0.11 0.60±0.10 −0.07

−10%

Kebapcilar et al.
2010 15)

38/38;
82%

3

SCH

T4

25-50

6

11.26±7.54

2.29±1.43

−8.97 −80% 0.64±0.13 0.63±0.12

−0.01

−1.6%

Cabral et al.
2011 30)

14/14;
100%

4

SCH

T4

44.23

12

6.79±2.0

3.02±0.89

−3.77 −56% 0.66±0.11 0.66±0.15

0

Köroglu et al.
2012 24)

30/30;
97%

4

SCH

T4

50

6

7.5±1.5

3.6±0.6

Akkoca et al.
2014 21)

20/20;
75%

3

SCH

T4

NR

7

8.97±1.1

2.94±0.43

−6.03 −67% 0.74±0.63 0.43±0.32

−0.31

−42%

Unsal et al.
2014 25)

56/56;
91%

1

SCH

T4

25-50

6

6.77±2.90

2.73±1.17

−4.04 −60% 0.53±0.11 0.51±0.13

−0.02

2%

Yazıcı et al.
2014 28)

23/23;
98%

4

SCH

T4

NR

6

5.9±1.2

1.7±0.9

−4.2 −71% 0.51±0.09 0.46±0.07

−0.05

10%

Cerbone et al.
2016 26)

39/39;
51%

2

SCH

T4

50

24

6.30±1.01

2.82±1.31

−3.48 −55% 0.44±0.08 0.46±0.07

0.02

4.5%

Niknam et al.
2016 27)

25/25;
60%

1

SCH

T4

50

2

7.19±1.29

2.56±0.69

−4.63 −64% 0.56±0.09 0.57±0.08

0.01

2%

−11.6 −88% 0.82±0.2

−3.9 −52%

NR

0.71±0.2

NR

NA

0%

NA

The JADAD score/scale or the Oxford quality scoring system, is a procedure to independently assess the methodological quality of a clinical trial.
SCH = Subclinical Hypothyroidism, TSH = Thyroid stimulating hormone.

A subgroup analysis was also conducted by considering TSH cut-off values as ≤ 10 mIU/l and ＞ 10
mIU/l in subjects with SCH and comparing their
CIMT values with those of EU controls at baseline.
Subjects with SCH with TSH ≤ 10.0 mU/l exhibited a
near significant increase in CIMT as compared to EU
controls at baseline; WMD was 0.36 mm with 95%
CI (−0.01, 0.73); p = 0.06 with significant heterogeneity; I2 = 68%; p = 0.009. However, WMD between
subjects with SCH with a mean TSH ＞ 10.0 mU/l
and EU controls was 0.61 with 95% CI (0.13, 1.10);
p ＜ 0.01, and heterogeneity was decreased to I2 = 56%;
p = 0.10. This shows that with a decreased betweenstudies heterogeneity, subjects with SCH with TSH
＞ 10.0 mU/l exhibited a significantly higher WMD
increase in CIMT as compared to SCH with TSH
≤ 10.0 mU/l when compared to EU controls (WMD

0.61 vs. 0.36). We also conducted a subgroup analysis
based on BMI groups. We calculated WMD with
95% CI by excluding all the studies with BMI ＞ 25
kg/m2 (as an increase in BMI is related to an increase
in CIMT). We used only those studies that reported a
mean BMI of subjects with SCH and EU as ＜ 25 kg/
m2. CIMT was still significantly higher in subjects
with SCH as compared to EU [WMD 0.51; 95% CI
(0.14, 0.89); p = 0.008] with significant heterogeneity,
I2 = 70%; p = 0.005. As increasing age, smoking, hypertension, diabetes, non-alcoholic fatty liver disease, dyslipidemia, polycystic ovarian disease, and menopause
are related to increased CIMT and increased CVD
risks, we removed all studies that discussed subjects
with SCH and EU controls with one or multiple of
these risk factors. The remaining 8 studies still showed
a significant increase in CIMT among subjects with
7
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Fig. 4a. WMD with 95% CI of CIMT in SCH and EU at baseline.

SCH as compared to EU controls [WMD 0.42; 95%
CI (0.09, 0.75); p = 0.01)] with significant heterogeneity, I2 = 68%; p = 0.002. The test for the overall effect
of CIMT differences in a subgroup analysis was significant with Z = 4.88; p ＜ 0.00001; with heterogeneity I2 = 64%; p ＜ 0.0001, and the test for subgroup differences was [Chi2 = 0.80, df = 3 (p = 0.85), I2 = 0%].
(Fig. 4b)
Effect of Thyroxin Treatment on CIMT Values in
Subjects with SCH
All 12 studies discussed the effects of thyroxin
treatment on CIMT reduction from pre- to posttreatment in subjects with SCH (n = 314) with the
duration of treatment ranging from 2 to 24 months;
however, 11 studies were included in the meta-analysis
as one study by Koroglu et al. 2012 24) did not report
the mean CIMT values in subjects with SCH at preand post-treatment with thyroxin. After treatment
with thyroxin in subjects with SCH, there was a statistically significant decrease in CIMT from pre- to posttreatment. In a fixed-effect model, the pooled WMD
of CIMT decrease in subjects with SCH from pre- to
post-treatment with thyroxin was −0.32 mm with
95% CI (−0.47, −0.16), p =＜ 0.0001 with heterogeneity, I2 = 2%; p = 0.42. CIMT of SCH treated subjects
was no longer different from matched EU subjects
with WMD of 0.13 mm and 95% CI (−0.04, 0.30);
p = 0.14 and heterogeneity, I2 = 27%; p = 0.20) (Data
not shown). (Figs. 5a & 5b)
A subgroup analysis was also conducted by considering prior thyroxin treatment TSH cut-off values
as ≤ 10 mIU/l and ＞ 10 mIU/l in subjects with SCH
and calculating the mean decrease in CIMT with thyroxin treatment from pre- to post-treatment periods.
WMD of a decrease in CIMT from pre- to post-treatment in subjects with SCH with a prior treatment
TSH ≤ 10 mIU/l was [WMD −0.30 mm; 95% CI
(−0.50, −0.10); p = 0.003); with heterogeneity, I2 =
8

5%; p = 0.39] and in subjects with SCH with a prior
treatment TSH ≥ 10 mIU/l was [WMD −0.35 mm;
95% CI (−0.61, −0.08); p = 0.010; with heterogeneity, I2 = 21%; p = 0.28]. Although WMD of a decrease
in CIMT with thyroxin treatment was higher in subjects with SCH with a prior treatment TSH ＞ 10
mIU/l as compared to those with TSH ≤ 10 mIU/l
(WMD −0.35 vs. −0.30), this subgroup analysis indicates that thyroxin treatment is effective in both groups
of subjects with SCH based on a prior treatment TSH
level (i.e., TSH as ≤ 10 mIU/l or TSH ≥ 10 mIU/l) in
significantly reducing CIMT. In a subgroup sensitivity
analysis by the duration of follow-up with thyroxin
treatment keeping 6 months of treatment as cut-off,
subjects with ＞ 6 months’ thyroxin treatment had a
higher decrease in CIMT from pre- to post-treatment
with WMD [−0.36.; 95% CI (−0.61, −0.12); p =
0.004] with heterogeneity I2 = 0% (p = 0.49), as compared to subjects with ≤ 6 months’ thyroxin treatment
with WMD [−0.28; 95% CI (−0.49, −0.08); p =
0.007] with heterogeneity I2 = 24% (p = 0.25). We also
conducted a subgroup analysis based on the JADAD
score. We excluded all low-quality studies with the
JADAD score ≤ 2. In all studies with the JADAD
score ≥ 3, WMD of a decrease in CIMT from preto post-treatment in subjects with SCH was [WMD
−0.40 mm; 95% CI (−0.61, −0.19); p = 0.0002);
with heterogeneity, I2 = 8%; p = 0.37]. In a subgroup
analysis, the test for the overall effect of CIMT reduction with thyroxin treatment was significant with Z =
5.54; p ＜0.00001; with heterogeneity I2 = 0%; p = 0.50,
and the test for subgroup differences was [Chi2 = 0.32,
df = 3 (p = 0.96), I2 = 0%]. (Fig. 5a).
Changes of Metabolic Parameters
Table 3 shows the differences in metabolic parameters between subjects with SCH and EU controls at
baseline as well as after thyroxin treatment in subjects
with SCH. As compared to EU controls, subjects with
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Fig. 4b. Subgroup analysis: WMD with 95% CI of CIMT in SCH and EU at baseline.

SCH had a significant increase in the levels of TC
[WMD, 0.71 mg/dl, 95% CI (0.23, 1.19); p = 0.004),
TG [WMD, 0.51 mg/dl, 95% CI (0.13, 0.90); p =
0.009], LDL [WMD, 0.63 mg/dl, 95% CI (0.30, 0.95);
p = 0.0001], SBP [WMD, 6.16 mmHg l, 95% CI (1.88,
10.45); p = 0.005], and DBP [WMD, 0.43 mmHg,
95% CI (0.11, 0.76); p = 0.009]. There was no significant difference in the HDL level in subjects with
SCH and EU at baseline [WMD, 0.02 mg/dl, 95%
CI (−0.24, 0.27); p = 0.90]. We also discussed the

changes in metabolic parameters in subjects with SCH
at pre- to post-treatment with thyroxin along a treatment follow-up period. As compared to pre-treatment
with thyroxin, the levels of TC (WMD, −0.53 mg/dl,
95% CI (−0.97, −0.09); p = 0.02), TG [WMD, −0.55
mg/dl, 95% CI (−0.96, −0.13); p = 0.01], LDL [WMD,
−0.57 mg/dl, 95% CI (−0.98, −0.15); p = 0.007], SBP
[WMD, −0.33 mmHg l, 95% CI (−0.62, −0.05);
p = 0.02], and DBP [WMD, −0.38 mmHg, 95% CI
(−0.68, −0.08); p = 0.01] were significantly decreased
9
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Fig. 5a. WMD with 95% CI of CIMT pre- to post-thyroxin Rx. in subjects with SCH.

at post-treatment with thyroxin. Thyroxin treatment
did not have any significant effect in increasing the
HDL levels as there was no significant change in HDL
(WMD, 0.03 mg/dl, 95% CI −0.16, 0.22; p = 0.75)
in subjects with SCH from pre- to post-treatment
with thyroxin.
Assessment of Publication Bias
We included at least 3 studies from a total of 12
studies that were eligible for this meta-analysis, which
discussed the comparison of CIMT values. To assess
any publication bias, we generated funnel plots of
effect estimates against their standard errors (on a
reversed scale) using free version of Review Manager
software 5 (RevMan) (Figs. 6 and 7). We assessed the
potential risk of publication bias through visual analysis of funnel plots. The studies reporting CIMT values
in subjects with SCH and EU controls at baseline
(n = 9) generated a roughly symmetrical funnel plot
indicating a positive standardized mean difference,
while 2 studies were published with significantly
higher values for a standardized mean difference and 1
study with a lower standardized mean difference. There
is little possibility of publication bias toward reporting
lower CIMT among EU controls. Studies reporting
CIMT from pre- to post-treatment with thyroxin in
subjects with SCH produced a symmetrical funnel
plot with a relatively low SE hinting at a low risk of
publication bias (Higgins 2011). One should be mindful that interpreting a funnel plot is subjective and an
asymmetric funnel plot could be generated due to
variability in selected sources, and it is not necessary
that an actual publication bias can lead to an asymmetrical funnel plot. We attempted to avoid bias in
study selection by defining our search criteria a priori.
These are discussed in detail under sensitivity analysis
as well as in limitations and strengths of the study. We
also addressed location bias by searching multiple
databases, which included studies that were conducted
10

in different countries or research settings in heterogeneous populations.
Medication doses provided to subjects with SCH
were not similar across the studies. To account for this
variability, we conducted a meta-regression analysis
and accounted for different dose-related information.
Results showed that there was an inverse relationship
between increasing medication dosage and low CIMT,
but the association was not significant. For each unit
increase in dose, CIMT decreased by 0.004 units (β:
−0.004; 95% CI: −0.03, 0.02; p ＞ 0.70). This could
be due to the limited number of studies (n = 9)
included in the model.
Discussion
We conducted a meta-analysis to demonstrate
the differences of CIMT values between subjects with
SCH and EU controls at baseline. We also provided
evidence of the effect of thyroxin treatment on CIMT
reduction in subjects with SCH from pre- to posttreatment. The main results of this meta-analysis were
as follows: (1) CIMT was significantly higher in subjects with SCH as compared to matched EU controls
at baseline. (2) Thyroxin treatment in subjects with
SCH was related to a significant reduction in CIMT
values from pre- to post-treatment over a follow-up
period and CIMT values in post-treated subjects with
SCH were no longer different from CIMT values of
matched EU controls. (3) More than 6 months of thyroxin treatment showed a higher reduction in CIMT
values as compared to less than 6 months of thyroxin
treatment. (4) As compared to EU controls, SCH was
also associated with a significant increase in TC, TG,
LDL, SBP, and DBP. (4) Thyroxin treatment in subjects with SCH was related to a significant reduction
in TC, TG, LDL, SBP, and DBP from pre- to posttreatment over a follow-up period. (5) Neither SCH
was associated with a low level of HDL nor the treat-
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Fig. 5b. Subgroup analysis: WMD with 95% CI of CIMT in subjects with SCH at pre- to post-treatment with thyroxin.

ment of SCH caused a significant increase in the
HDL level.
There is an increasing body of literature associating SCH with possible subclinical as well as clinical
CVD outcomes 15, 17, 18, 20-28, 34). The subclinical CVD
outcome can be presented as increased inflammatory
markers, risk of hypertension, lipid disorders,
increased CIMT, endothelial dysfunction, and arterial
stiffness 17, 18, 22-26, 28, 35-40). Furthermore, some studies
emphasized a positive association between SCH and

clinical CVD outcomes, such as heart failure progression with less evidence in the oldest old population 41, 42).
Rodondi et al. showed in a meta-analysis that SCH
was associated with an increased risk of CHD 43). In
another meta-analysis of 11 prospective cohort studies, Rodondi et al. showed that SCH was associated
with an increased risk of coronary heart disease
(CHD) events and mortality. Such risk was greater
among those with higher TSH levels, predominantly
among those with a TSH level ≥ 10 mIU/L 44). Accord11
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Table 3. Metabolic Parameters at baseline in Subclinical Hypothyroid (SCH) subjects and Euthyroid (EU) controls and at Pre-andPost Rx with thyroxin in SCH subjects.
Metabolic Parameters at baseline b/w SCH and EU groups
Studies Sample size
#
(SCH/EU)

WMD
(95%CI)

I2 Statistic
P value
%; P

Changes of Metabolic Parameters at pre-and-post thyroxin Rx in SCH
# of Sample size SCH
studies (Pre-Rx/Post-Rx)

WMD
(95%CI)

I2 Statistic
%; P

P value

TC

11

324/321

0.71
[0.23, 1.19]

87%;
0.00001

0.004

10

299/295

−0.53
[−0.97, −0.09]

85%;
0.00001

0.02

TG

11

324/321

0.51
[0.13, 0.90]

81%;
0.00001

0.009

10

299/295

−0.55
[−0.96, −0.13]

83%;
0.00001

0.01

LDL

12

380/367

0.63
[0.30, 0.95]

78%;
0.00001

0.0001

10

299/295

−0.57
[−0.98, −0.15]

83%;
0.00001

0.007

HDL

12

380/367

0.02
[−0.24, 0.27]

65%;
0.0009

0.90

8

224/220

0.03
[−0.16, 0.22]

0%;
0.57

0.75

SBP

8

265/258

6.16
[1.88, 10.45]

62%;
0.009

0.005

6

209/205

−0.33
[−0.62, −0.05]

52%;
0.07

0.02

DBP

8

265/258

0.43
[0.11, 0.76]

69%;
0.002

0.009

6

209/205

−0.38
[−0.68, −0.08]

56%;
0.04

0.01

TC = Total cholesterol, TG = Triglycerides, LDL = Low density lipoprotein, HDL = High density lipoprotein, SBP = Systolic Blood Pressure,
DBP = Diastolic Blood Pressure.

ing to some studies, SCH is not only related to worse
CVD outcomes but also associated with pregnancy
outcomes, infertility, other neuropsychiatric issues,
and even cancer mortality 45, 46). However, few studies
failed to demonstrate such association between SCH
and CVD outcomes 47). Capola et al. showed a strong
association between SCH and atrial fibrillation but
did not support the association between SCH with
other CVD-related morbidity and mortality 48, 49). The
main reason for the lack of evidence could be the use
of a small sample size. The main mechanism of development of CVD in SCH could be related to lowgrade chronic inflammation, abnormal lipid profile,
insulin resistance, oxidative stress, arterial stiffness, and
endothelial dysfunction 38, 50-52). Moreover, these risk
factors are accelerated in case of progression of SCH
to overt thyroid disorders because there is a minimum
of 2 to 5% per year to a maximum of 5 to 8% per
year risk of progression of SCH to overt hypothyroidism depending on the degree of serum TSH elevation 53-55).
There is also an increasing controversy on whether
or not subjects with SCH should be treated. Most
research workers agree with treating SCH with persistent serum TSH ≥ 10.0 mIU/L and following an individualized therapy for those with TSH ＜ 10.0 mIU/
L 54). This is because the risk of CVD increases as the
TSH level increases beyond 10 mIU/L. The 2013
ETA Guidelines recommended thyroxin treatment of
young patients with SCH ( ＜ 70 years) if TSH ≥ 10
12

mIU/L, and followed an individualized approach in
young patients with SCH ( ＜ 70 years) with TSH ≤ 10
mIU/L depending upon the presence and absence of
symptoms of SCH. These guidelines recommended
following the age-specific local reference ranges for
serum TSH levels to decide in taking a step to treat
subjects with SCH or simply follow-up with monitoring of TSH in both situations 55). Our meta-analysis
showed a significant increased CIMT in subjects with
SCH versus EU controls only at TSH values of ＞ 10.0
mIU/l, but showed a near significant increase in
CIMT at TSH values of ≤ 10.0 mIU/l. However, this
review emphasizes thyroxin treatment of subjects with
SCH at any level of TSH, because such treatment has
a significant effect on CIMT reduction both at a prior
treatment TSH ≤ 10.0 mU/l as well as TSH ＞ 10.0
mU/l (Fig. 5b). We also observed that subjects with
SCH with a prior treatment TSH ＞ 10.0 mU/l exhibited a significantly higher WMD decrease in CIMT as
compared to SCH with a prior treatment TSH ≤ 10.0
mU/l (WMD −0.35 vs. −0.30), but both showed a
significant CIMT reduction from pre- to post-treatment. Some studies report against treating SCH
because these studies did not find any evidence of
SCH association with CVD outcomes at any level of
TSH meeting SCH diagnosis. The study by Cappola
et al. did not find any association between SCH and
incidence and prevalence of atherosclerotic disease, as
well as showed no significant positive effect on CVD
outcome with thyroxin treatment 56).
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Fig. 6. Funnel plot of CIMT values in subjects with SCH and EU at baseline.

Our meta-analysis provided a strong evidence of
increased subclinical CVD risks as increased CIMT,
higher-level atherogenic lipids, and increased SBP and
DBP in subjects with SCH. An increase in CIMT was
significantly correlated with an increase in the level of
atherogenic lipids. The altered lipid levels could be the
major mechanism causing early atherosclerotic vascular changes in subjects with SCH. In all subgroup
analyses, the association between increased CIMT in
subjects with SCH remained significant except in subjects with SCH with a mean TSH ≤ 10.0 mIU/l,
where SCH was no longer associated with an increased
CIMT. Furthermore, we found a greater improvement
in CIMT values in subjects with SCH with a thyroxin
treatment duration of more than 6 months versus less
than 6 months (WMD of CIMT reduction −0.36 vs.
−0.28). Many studies vote for a lifelong treatment
with thyroxin and a regular monitoring of thyroid
function tests for clinical/overt hypothyroidism; however, no robust evidence exists regarding the duration
of long-term treatment of otherwise healthy subjects
with SCH. Moreover, some studies suggest little or no
symptomatic benefit from the treatment of SCH 57-59).
According to the 2013 SCH treatment guidelines by
Pearce et al., there is emphasis on starting the treatment of SCH if a patient has signs and symptoms or
other conditions, such as diffuse or nodular goiter,
diabetes, dyslipidemia, or TSH ＞ 10 mU/l, and if there
is an improvement in symptoms, then to consider a
lifelong treatment 55). Our meta-analysis also showed a
significant risk of an increase in CIMT and dyslipidemia especially at TSH ＞ 10.0 mU/l and recommended
the start of thyroxin treatment in SCH in otherwise

healthy young subjects. A meta-analysis by Goa et al.
showed that SCH was associated with only SBP but
not DBP 34), but a meta-analysis by Cai et al. 60) and
the present meta-analysis showed that SCH was significantly associated with higher SBP as well as higher
DBP when compared with matched EU controls. Furthermore, this meta-analysis also observed a significant
decrease in both SBP (p = 0.02) and DBP (p = 0.01)
with thyroxin treatment. This evidence suggested that
subjects with SCH are at a significantly higher risk of
subclinical CVD risk factors and can obtain benefits
from in time long-term thyroxin treatment.
The strengths of the present meta-analysis are as
follows: (1) We defined a strict inclusion and exclusion criteria. (2) We conducted a different subgroup
analysis to reduce heterogeneity and publication bias.
(3) We also conducted an analysis for CIMT differences in subjects with SCH and EU controls after
removing all studies that used subjects with any other
conditions, which can potentially affect CIMT; for
example, subjects with a history of smoking, hypertension, and diabetes, obese with non-alcoholic fatty
liver disease, with BMI ＞ 25 kg/m2, subjects with Polycystic Ovary Syndrome (PCOS); the results were still
significant. (4) We conducted the dose meta-regression, which showed that an increase in each unit thyroxin dose has an addictive effect on CIMT reduction,
although the model was not significant due to the limited number of studies included in the model.
The present meta-analysis has the following limitations: (1) Most of the clinical trials discussing the
treatment of subjects with SCH were not doubleblind, randomized controlled trials; however, such
13
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Fig. 7. Funnel plot of CIMT pre- to post-thyroxin Rx. in subjects with SCH.
Abbreviations: SCH: Subclinical hypothyroidism/Subclinical hypothyroid, EU: Euthyroid/
Controls

approach would be linked with a less bias. (2) There
was significant heterogeneity among the studies discussing baseline differences among CIMT values in
SCH and EU controls, although a subgroup analysis
was conducted to calculate the less biased association
between SCH and CVD risk factors. The main reasons for heterogeneity would be related to the differences across the studies included in the review, such as
great variations in sample size, type of study population used, study design, different TSH cut-off value to
diagnose SCH, differences in inclusion and exclusion
criteria, the method of TSH and CIMT measurements, and different confounding factors used for
adjustment. (3) The duration of treatment was quite
broad ranging from 2 months to 24 months, which
can potentially create a bias, although we conducted a
subgroup analysis keeping the cut-off treatment duration as 6 months and noticed that the benefit of CVD
risks is greater with the treatment duration longer
than 6 months. Randomized controlled clinical trials
with longer treatment durations are needed to verify
these changes. (4) We could not conduct a subgroup
analysis of specific gender’s (females vs. males) risk of
SCH with CIMT changes because some studies did
not clearly provide such information. (5) The studies
used in this meta-analysis used a broad age range,
which could be another source of heterogeneity. (6)
Heterogeneity could be due to a selection or language
bias as we used articles from all languages; citation
bias as “negative” studies are quoted less frequently
14

and, therefore, are more likely to be missed in the
search for relevant trials. All these types of biases are
more likely to affect studies with smaller participants
to a greater degree than large trials.
Conclusion
In summary, this meta-analysis suggests that
there is a strong association of SCH and increased
CIMT, along with dyslipidemia and increased SBP
and DBP. Such association has been proven by many
other studies. The increased CIMT could be related to
the associated increase in TSH level, dyslipidemia,
obesity, and hypertension. This meta-analysis also suggests that thyroxin treatment has significant beneficial
effects on CIMT reduction, weight, hypertension, and
a positive improvement in lipids, especially thyroxin
treatment longer than 6 months. Double-blind, randomized controlled clinical trials with a longer duration of follow-up are needed to clearly delineate the
risk of SCH with CVD risk factors.
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Abbreviations Frequently Used in
This Manuscript
SCH: Subclinical hypothyroidism/subclinical
hypothyroid
EU: Euthyroid (controls)
CIMT: Carotid Intima – Media Thickness
T4: Thyroxin treatment
TC: Total cholesterol
TG: Triglycerides
LDL: Low-density lipoprotein
HDL: High-density lipoprotein
SBP: Systolic blood pressure
DBP: Diastolic blood pressure
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